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Abstract 
 Proteomics is a research field aiming to characterize molecular and cellular dynamics 
in protein expression and function on a global level. The introduction of proteomics has been 
greatly broadening our view and accelerating our path in various medical researches. The 
most significant advantage of proteomics is its ability to examine a whole proteome or sub-
proteome in a single experiment so that the protein alterations corresponding to a 
pathological or biochemical condition at a given time can be considered in an integrated way. 
Proteomic technology has been extensively used to tackle a wide variety of medical subjects 
including biomarker discovery and drug development. By complement with other new 
technique advances in genomics and bioinformatics, proteomics has a great potential to make 
considerable contribution to biomarker identification and to revolutionize drug development 
process. This article provides a brief overview of the proteomic technologies and their 
application in biomarker discovery and drug development. 
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INTRODUCTION 
 The rapid progresses in genomics and spectacular advances in mass spectroscopic 
technology in last several years have led us into a new field, proteomics. Today, proteomics 
has been growing to be a revolutionary tool in various studies in molecular medicine 
including biomarker discovery and drug development. Disease involves alterations in protein 
expression and thus offers a basis for detection of biomarkers and drug targets through 
examining the protein expression profiles with proteomics. By directly analyzing proteins in 
body fluids including serum, spinal fluid, urine and exhaled breath, proteomics can globally 
identify and monitor biomarkers and thus change the way we diagnose, treat and prevent 
disease. By comprehensively inspecting the entire proteome in given tissues or cells treated 
with drug or drug candidates, proteomics provides a detailed map of protein interactions 
related to disease-associated pathways thus facilitate drug development. In this review article, 
we aim to briefly summarize the technology of proteomics and its application in biomarker 
discovery and drug development. 
 
Definition of Proteomics 
Proteome refers to the entire protein complement expressed by a genome and 
proteomics is the study of the proteome [Wasinger et al., 1995; Wilkins et al., 1996]. Since 
the proteome is dynamic, proteomics can be defined as a research field that involves the 
large-scale identification, characterization and quantitation of proteins expressed in a cell 
line, tissue or organism under given conditions. Proteomocs is a powerful approach that 
integrates recent technological advances in high-throughput protein separation, mass 
spectrometry, genomic database and bioinformatics to address important physiological and 
medical questions.  
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Protein Expression and Modification 
Proteins, not genes, are functional molecules in cells and represent important targets 
for the therapeutic intervention. It is impossible to accurately predict genes and their 
structures by genomic data and bioinformatics. Only through the study of proteins can the 
existence of a particular gene be confirmed and the function of the protein expressed by the 
gene be characterized. Moreover, protein expression and the expression level are not the 
direct reflection of the mRNA levels in cells and protein expression also subjects to 
posttranslational modification that exists in hundreds different types. As a result, a gene could 
express different types of proteins with different amounts under different conditions. These 
varied phenotypes are responsible for the actual biological functions of a gene in cells. 
Proteomics is established to address these problems. The applications of proteomics include 
the study of protein expression and modification under a given biological condition, the 
characterization of protein functions in a genome, the identification of protein localization 
and compartmentalization at a given time, and the determination of protein-protein 
interactions related to a biological process. In this regard, proteomics can be classified into 
three main types, expression proteomics, functional proteomics and structural proteomics 
[Graves and Haystead 2002].  
Expression proteomics 
Expression proteomics looks at the different display of proteins expressed in a given 
tissue, body fluid or cell and thus searches for biomarkers and/or drug targets. In this 
approach, entire protein extracts are separated to generate protein profiles. By comparing the 
protein profiles between a health or control sample and a diseased or drug-treated sample, 
proteins altered in their expression levels and patterns (e.g. modification) are identified. 
Further characterization can determine if these proteins are disease-specific or drug-
associated targets.  
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Functional proteomics 
Functional proteomics focuses on a group of proteins assembling a specific biological 
function and studies their protein-protein or protein-DNA/RNA interactions and post-
translational modifications. Specific types of proteins or sub-proteomes are isolated through 
affinity chromatography or other chemical method and then subjected to further proteomics 
analysis based on how these proteins in the biological system interact with each other, in 
pairs or in protein complexes, within complicated cellular pathways. This approach allows a 
selected group of proteins to be characterized in response to internal or external signals and 
thus provides information about protein signaling, disease pathogenesis and protein-drug 
interactions.  
Structural proteomics 
Structural proteomics aims at mapping out the structures of all the proteins or protein 
complexes in a specific cellular organelle and building up the relationships of these proteins 
in a global view. This type of approach attempts to characterize all the proteins in a genome 
and integrate their protein-protein interactions into a “proteomics map” with “functional, 
structural and location annotation”. One can also isolate or pre-fragment the proteins or 
protein complexes from specific organelles and then analyze their locations and their 
relations with other proteins which make up the functional characteristics of these organelles. 
 
TECHNOLOGY PLATFORMS OF PROTEOMICS 
 There are several proteomic platforms available at the moment.  A typical workflow 
of a platform generally consists of, in subsequence, sample preparation or extraction, protein 
separation or pre-fractionation, comparative profiling of protein expressions, proteolytic 
digestion and mass analysis, protein identification through database matching or protein 
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sequencing, and finally protein validation and biochemical characterization. The commonly 
used proteomic techniques are briefly introduced as follows. 
2-D gel electrophoresis 
 The first and most commonly used technique in proteomics is 2-dimensional gel 
electrophoresis (2-DE). In 2-DE, proteins are extracted from cells or tissues and then 
separated according to their isoelectric points (pIs) in the first dimension and their molecular 
weights in the second dimension to generate protein profiles. 2-DE has a powerful resolution 
of separating thousands of proteins in a single gel, a capacity that no other method can 
overpass in protein separation up today. After 2-DE separation, proteins in gels can be 
visualized by Coomasie blue or silver staining and gel images are digitalized and analyzed 
with a computer-aid special software. Interesting (altered) protein spots are identified, cut off 
and subjected to in-gel tryptic digestion. The resulting peptide mixtures are analyzed with 
mass spectrometry (MS) to obtain so-called peptide fingerprints which determine protein 
identifications through matching to genomic and proteomic databases. 
     2-DE is primarily used in expression proteomics in which protein profiles are 
compared qualitatively and quantitatively between any given sample pair. The appearance 
and disappearance of protein spots tell the difference of protein expression while the varied 
intensity of the spots reflects the different protein expression levels under a given condition. 
2-DE protein profiling is especially useful in biomarker discovery in which comparison can 
be made between normal and diseased samples including tumor tissues and bodily fluids. 2-
DE also features a great strength of separating protein isoforms resulting from protein 
posttranslational modifications, alternative mRNA splicing and proteolytic processing due to 
a disease condition or drug treatment. These kinds of protein modifications and cellular 
processing change the molecular mass and the pI (charge) of proteins leading to the 
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appearance of different spots in 2-D gels. This resolving ability of 2-DE has been extensively 
employed in the studies of functional and structural proteomics.   
Mass spectrometry 
 After protein separation by 2-DE, MS is applied to produce mass spectra for protein 
identification. MS is an analytic tool to obtain protein structural information such as peptide 
masses, amino acid sequences, type and location of protein modification. The recently 
tremendous improvement of MS in sensitivity, resolution and mass accuracy made this 
analytic tool a core technology in proteomics. Before MS analysis, proteins are subjected to 
“in-gel” digestion with a protease and the proteolytic peptides are extracted from the gels. 
When applied to MS, protein peptides are ionized with a “soft” ion source, and the ionized 
peptide mixture is resolved in a mass analyzer based on the mass/charge (m/z) ratio of the 
peptides, which are then detected in sequence by a detector and are finally displayed from 
low to higher mass as a mass spectrum.     
 The most widely used MS is matrix-assisted laser desorption ionization time of flight 
mass spectrometry (MALDI-TOF MS) [Yates 1996; Yates, III 1998]. With MALDI-TOF, 
digested peptides are mixed with a chemical matrix that can absorb energy from light, and the 
mixture is co-crystallized in spots on a sample plate. When a laser beam fires at the spots, the 
matrix absorbs energy and transfers it to the peptides which “flight” in gas phase by picking 
up a proton and thus being charged. These ionized spices are then resolved by their different 
flight time in a high-vacuum tube to reach the detector. For most proteins, ~10 ng (200 fmol 
for a 50-kD protein) can be reliably detected by MALDI-TOF. MALDI-TOF is principally 
used in peptide mass fingerprinting and is a primary instrument in large-scale proteomics 
because it can be integrated into a high-throughput automatic workflow of proteomics.   
 Another frequently used MS in proteomics is nano electrospray ionization tandem MS 
(ESI MS/MS) [Yates, III et al., 1997; Yates, III et al., 1999]. In ESI MS/MS, a microcapillary 
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tube containing 1 μl of peptide solution sprays a fine mist of charged droplets generated from 
a potential difference between the capillary and the inlet to the mass spectrometer. 
Desolvated peptide ions are formed as the solvent evaporated in a high vacuum chamber, and 
are resolved to produce the first MS scan. From the MS scan, a peptide ion (parent ion) is 
selectively transmitted into a collision chamber where the peptide is fragmented by 
interactions with an inert gas. The fragments of the peptide ion are then resolved based on 
their m/z ratio to generate the second MS spectrum with a series of small peptides that differ 
by only a single amino acid. By combining these small peptides together, the amino acid 
sequence of the parent peptide can be constructed.  
 In routine proteomics, proteins in question are generally analyzed firstly with 
MALDI-TOF MS through peptide fingerprinting. If proteins cannot be identified by 
fingerprinting due to insufficient number of proteolytic peptides or lacking suitable DNA 
database for confident matching, ESI MS/MS can be used for the amino acid sequencing. 
These two types of MS operate in different ways and produce complementary information 
suitable for protein identification and thus stay in the mainstream of the technology of 
proteomics.  
SELDI-ProteinChip separation and profiling 
 SELDI-ProteinChip system is a newly developed proteomics platform that uses 
patented technology to separate, profile and analyze proteins at the femtomole level [Jr et al., 
1999; Yip and Lomas 2002]. With this approach, the surface of a protein chip is modified 
chemically or biochemically (Surface Enhanced) to be able to bind a certain group of proteins 
based on a specific physical property such as hydrophobicity, charge, etc. A small amount of 
crude biological sample such as serum or protein extracts is directly applied to the surface, 
incubated and washed. The specific proteins or functional class of proteins that match to the 
chemical or biochemical properties of the protein chip are retained on the surface and 
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therefore separated from the protein mixture. The protein chip is then subjected to mass 
analysis by a ProteinChip reader (a SELDI-TOF MS) which generates mass profiles of the 
bound proteins in spectral or gel views. SELDI-ProteinChip system allows comparison of 
protein mass profiles to be made between any sample pair or among a group of samples from 
different biological conditions, and thus biomarkers or disease-related protein targets are 
identified. The great advantages of this technology include its abilities to use a very small 
amount of crude sample and to detect proteins with molecular weights lower than 6-kDa, 
which may not be observed in 2-DE in general.   
Protein pre-fractionation and “short-gun” approach 
 Differing from the 2-DE/MALDI-TOF and SELDI-ProteinChip techniques stated 
above mainly focusing on protein differential expression, a new approach called “short-gun” 
or LC-MS/MS aims at total identification of entire proteins [McCormack et al., 1997; Peng 
and Gygi 2001]. This method uses reversed-phase liquid chromatography (LC) to separate 
the tryptic digests of entire proteins followed by on-line ESI tandem MS for peptide 
sequencing. In this approach, total protein extracts from cells or tissue are pre-fractioned with 
an anion exchange column to simplify the protein mixture. Selections of protein fractions 
from the column are subjected to proteolytic digestion, and the resulting digested mixture is 
applied to LC separation coupled online with MS/MS measurement. The generated MS 
spectra of whole cellular fraction are carefully analyzed and protein identification is 
performed through peptide assignment and database searching. This short-gun approach 
features less sample manipulation and total protein peptide mapping. A recent study 
integrating this technique with a “top-down” approach (intact protein mass analysis followed 
by molecular weight database search) substantially increased the dynamic range and 
confidence of protein identification [VerBerkmoes et al., 2002].    
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ICAT modification and chemical proteomics 
 As an alternative to 2-DE separation, a recently introduced method, known as isotope-
coded affinity tags (ICAT) [Gygi et al., 1999], can be used for protein expression profiling. 
This technique depends on the chemical labeling of any pair of protein samples with two 
identical reagents isotopically different in mass, allowing the relative amount of protein to be 
quantitatively compared in the subsequent mass spectral determination. With ICAT 
modification, the pair of protein samples are labeled on their cystine residues respectively 
with either light or heavy form of ICAT chemical reagents and then mixed together for 
proteolytic digestion. The digested peptide mixture is further purified through avidin affinity 
chromatography by means of the biotin tag on ICAT reagents to isolate the ICAT-labeled 
peptides. MS analysis of these peptides produces the peak ratios for different protein 
expression and subsequent MS/MS peptide sequencing results in identification of proteins in 
altered expression levels.    
 Similar strategies using specific protein-modifying reagents (tags) in facilitating 
expression profiling and functional studies of distinct protein families within a complex 
proteome is now classified as chemical proteomics [Jeffery and Bogyo 2003]. These 
modifying reagents are designed and synthesized to be able to selectively react with distinct 
protein residues or protein families mechanistically or functionally. The modified proteins 
can be purified or isolated based on their tag properties and then the targeted proteins can be 
identified and/or further characterized with MS. Chemical proteomics has great potential in 
accelerating the studies of target identification and validation and drug discovery.  
 
APPLICATION OF PROTEOMICS IN BIOMARKER DISCOVERY 
 Biomarkers are usually disease-associated proteins that can be detected and 
quantitatively measured for disease diagnosis, staging, prognosis and treatment monitoring. 
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The development of a disease condition is a multi-step process involving different biological 
pathways. Many proteins are altered in expression levels and/or expression types such as 
modification during this process. These altered proteins can be detected in tissue, blood, urine 
or other body fluids and thus provide indicators for the disease. An ideal biomarker should 
have high specificity for a certain disease condition; this kind of biomarkers is rare, however. 
Most of biomarkers are those proteins expressed by many different types of diseases but with 
variant expression levels from type to type. Combining several unspecific biomarkers 
together may lead to a specific index for a particular disease. In this regard, proteomics offers 
suitable and powerful technique platforms for the biomarker discovery, characterization and 
evaluation because of its capacity of globally examining the protein expression profiles under 
given conditions. Actually, since they were introduced, proteomics approaches, especially 2-
DE/MALDI-TOF and SELDI/ProteinChip, have been extensively used to identify biomarkers 
for various diseases. 
Cancer 
 Cancer is a prime target to study by proteomics. Lung cancer is one of most 
comprehensively studied malignancies using proteomics techniques. Substantial effort was 
made by Hanash and co-workers, together with other researchers, to identify tumor-
associated proteins as novel biomarkers for the early diagnosis and/or as new targets for 
therapeutic treatment [Hanash et al., 2001; Hanash 2001; Naour et al., 2002; Wang and 
Hanash 2002]. A number of potential tumor markers have been found in tissue, sera or tumor 
cells by using comparative 2DE technique coupled with MS and microarray analysis or 
autoantibodies blotting [Brichory et al., 2001a; Brichory et al., 2001b; Chang et al., 2001; 
Chen et al., 2002a; Madoz-Gurpide et al., 2001]. Especially, cytokeratin isoforms were 
demonstrated to correlate with patient survival in the cancer [Gharib et al., 2002] and the 
over-expression of oncoprotein 18 was found to reflect the poor differentiation status in lung 
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carcinoma [Chen et al., 2003]. A database integrated protein expression with mRNA levels in 
lung cancer has also been constructed to facilitate biomarker discovery and tumor 
classification [Oh et al., 2001]. To study the arsenic-induced cell transformation of lung 
cancer, we have performed a proteomic analysis by using SELDI-TOF ProteinChip 
technology [He et al., 2003a]. Differential protein profiles between control and arsenic-
induced transformed lung cells distinguished several prominent protein peaks, indicating the 
potential of SELDI proteomics for identifying biomarkers for lung cancer [He et al., 2003a].   
 Another cancer that received extensive proteomics analysis is bladder tumor, 
including transitional cell carcinoma (TCC), squamous cell carcinoma (SCC) and 
adenocarcinoma. Celis research group has long been involved in the searching for biomarkers 
that may form the basis for diagnosis, prognosis and treatment of bladder cancer using 
proteome expression profiling [Celis et al., 1999d; Celis et al., 2000; Celis and Gromov 
2003]. They have systematically analyzed hundreds of fresh tumors, random biopsies, 
cystectomies and urines using proteomics and immunohistochemical analysis to establish 
comprehensive 2-DE databases of bladder cancer for tumor marker and protein target 
discovery [Celis et al., 1999c; Rasmussen et al., 1996]. Their studies also led to the 
identification of several protein markers associated with TCC progression [Celis et al., 1996; 
Gromova et al., 1998] and SCC differentiation [Celis et al., 1999b; Ostergaard et al., 1997] 
and invasion [Celis et al., 1999a; Ostergaard et al., 1999]. In addition, ProteinChip 
technology has also been utilized to screen urine samples from TCC patients and five 
potential novel TCC biomarkers have been found through the study [Vlahou et al., 2001].   
 Many investigators have also concentrated on the identification of biomarkers for 
breast cancer [Hondermarck et al., 2001; Luftner and Possinger 2002; Wulfkuhle et al., 
2001]. Again, 2DE protein profiling was used as a major approach to search for tumor-related 
proteins in tumor tissues [Franzen et al., 1996; Wulfkuhle et al., 2002] and breast tumor cells 
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[Adam et al., 2003; Le Naour et al., 2001], while SELDI-ProteinChip was a sensitive tool to 
detect new biomarkers in serum [Li et al., 2002] and nipple aspiration fluid [Cho et al., 2002; 
Paweletz et al., 2001b]. In the unique case of breast cancer, the biomarker discovery in nipple 
aspirate fluid features an even special significance as it may lead to a potential non-invasive 
method in the diagnosis of the disease. A recent elegant experiment used bilateral matched 
pair breast ductal fluids from women with unilateral invasive breast carcinoma as specimens 
to examine protein expressions distinct between the breast pair with 2DE proteomics [Kuerer 
et al., 2002]. This study has identified several differently expressed proteins that are 
associated with breast carcinoma and may be potential biomarkers with a clinical role.      
 Since the current clinical biomarker, prostate-specific antigen (PSA), lacks the 
specificity and sensitivity in the diagnosis of prostate cancer, efforts were made to analyze 
multiple proteins as signature proteomic patterns for distinguishing cancer from noncancer 
and thus as an index of biomarkers for accurate detection of prostate cancer [Adam et al., 
2002a; Petricoin, III et al., 2002; Qu et al., 2002]. Researchers also looked for alternatives of 
PSA by examining the proteomic alternations of PSA-antichymotrypsin complex [Qian et al., 
1997], low-MW PSA [Charrier et al., 2001], and other tumor-associated proteins such as 
nuclear matrix proteins [Alberti et al., 2000; Lakshmanan et al., 1998]. In particular, 
improvements in sensitivity and accuracy have been obtained by applying laser capture 
microdissection (LCM) to accumulate tumor cells from tissue samples prior to 
SELDI/ProteinChip [Jr et al., 1999; Wellmann et al., 2002] or 2DE/MALDI [Ahram et al., 
2002; Ornstein et al., 2000; Paweletz et al., 2001a] proteomic analysis. These studies have 
resulted in identification of a number of unique proteins that are associated with the actual 
molecular events in carcinogenesis and may be potential candidates for new specific 
biomarkers.   
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 Lacking specific biomarkers in clinical assessment is also the problem for 
hepatocellular carcinoma (HCC). Attempts have been taken to discover novel biomarkers for 
HCC early detection by means of proteomics [Seow et al., 2001; Shalhoub et al., 2001; Steel 
et al., 2001]. These include the identification of two HCC specific nuclear matrix proteins 
[Chew et al., 1997], novel protein Hcc-1 [Choong et al., 2001], a distinct repertoire of 
autoantibodies in HCC [Le Naour et al., 2002], aldehyde dehydrogenase variants [Park et al., 
2002] and sarcosine dehydrogenase, liver carboxylesterase, peptidyl-prolyl isomerase A and 
lamin B1 [Lim et al., 2002]. In addition, proteome databases have been also established to aid 
in pathological staging, protein profiling and biomarker discovering of HCC [Cho et al., 
2002; Liang et al., 2002; Seow et al., 2000].   
 Gastric and colon cancers are two common malignant tumors in digestive tract. Both 
diseases are traditionally identified and classified by histological criteria due to no specific 
and suitable biomarkers currently available for clinical assessment. However, only a limit 
number of proteomic studies involved in the direct discovery of biomarkers for these cancers, 
although proteome databases of tissue [Cole et al., 2000; Ha et al., 2002] and cell lines 
[Hoffmann et al., 2001; Simpson et al., 2000; Tomlinson et al., 2002] have been constructed. 
So far, attentions have been attracted to identify specific proteins or antigens that reflect the 
chemo- and thermo-resistant properties of stomach cancer [Sinha et al., 1998; Sinha et al., 
2001] and that are associated with Helicobacter pylori, the human pathogen that causes an 
inflammatory process leading to gastric cancer [Chang et al., 1999; Enroth et al., 2000; Haas 
et al., 2002]. For colon cancer, a few candidate proteins have been found in tissue samples to 
be potential markers for correlating to malignant transformation and tumor metastasis 
[Brunagel et al., 2002; Chaurand et al., 2001a; Chaurand et al., 2001b; Keesee et al., 1994; 
Stulik et al., 2001].  
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 Other cancers that received proteomic analysis for biomarker or antigen identification 
include ovarian cancer [Ardekani et al., 2002; Bandera et al., 2003; Liotta et al., 2003], renal 
cell carcinoma [Balabanov et al., 2001; Klade et al., 2001; Sarto et al., 1999], head and neck 
cancer [Patel et al., 2001; Srisomsap et al., 2002; Zhou et al., 2002], neuroblastoma 
[Prasannan et al., 2000] and leukemia [Hanash et al., 2002]. One recent study using 2DE to 
analyze LCM ovarian tumor specimens revealed several uniquely over-expressed proteins in 
invasive cancer, which could be important markers and/or therapeutic targets [Jones et al., 
2002]. Another worth-emphasized project utilized a serological proteomic pattern generated 
through SELDI technology as a screening tool to classify 116 masked serum samples and 
yielded a sensitivity of 100% and specificity of 95% in discriminating ovarian cancer from 
non-cancer [Petricoin et al., 2002].  A new emerging proteomic technology, differential in-gel 
electrophoresis (DIGE), in combination with LCM, has also been claimed to be a powerful 
procedure for the molecular characterization of tumor progression and for the identification 
of tumor-specific biomarkers in esophageal scans cell cancer [Zhou et al., 2002].  
Heart disease 
 Heart disease, including various cardiovascular dysfunctions, is a leading cause of 
death in the world. This is partially due to the lack of sensitive biomarkers for diagnosis and 
the limited option of therapeutic treatments. Although the pathogenic mechanisms of 
cardiovascular diseases remind largely unknown, it can be speculated that extensive 
alternations of myocardial proteins accompany the disease processes and determine the 
progression and prognosis. Researchers in this area promptly realized that proteomics is a 
robust tool to globally characterize these underlying protein changes for better understanding 
of the basis of heart disease and for identification of novel target proteins for diagnosis and 
therapy [Arrell et al., 2001b; Dunn 2000; Jager et al., 2002; Jiang et al., 2001; Macri and 
Rapundalo 2001; Van Eyk 2001].  
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 As the pioneering work, several proteomic databases of human, dog and rat 
myocardial tissues were constructed by Jungblut [Li et al., 1999; Muller et al., 1996; Otto et 
al., 1996], Dunn [Dunn et al., 1997; Evans et al., 1997], and Pleissner [Pleissner et al., 1996] 
and their colleagues. These databases contain information on several hundred identified 
cardiac proteins and thus build a basis for studying alternations in protein expression in 
models of heart disease. Recently, completed identification and characterization of bovine 
heart proteins was also achieved by using 2DE separation coupled with a new high-resolution 
MS, MALDI-TOF/TOF, which displayed both protein identify and modification on 
tryptophan residues [Bienvenut et al., 2002]. In addition, an Oxford team has reported the 
generation of a high-resolution 2DE proteomic map of platelets, a crucial factor correlated 
with thrombotic diseases such as stroke and myocardial infarction [O'Neill et al., 2002]. All 
these databases form an essential platform for cardiovascular proteomics in facilitating future 
identification of biomarkers and drug targets for new therapeutic strategies. Along with these 
database construction, to better separate the complex proteins from cardiac muscles for 
protein identification, various improved methods have been developed by enhancing the 
solubilization [Labugger et al., 2002], pre-fractioning sub-proteomes [McDonough et al., 
2002; Neverova and Van Eyk 2002] and complementing separation techniques with LC-
MS/MS [Edmondson et al., 2002]. 
 Based on these databases and later-on proteomic characterization, several animal 
models have been employed in proteomic studies for analyzing functional proteins differently 
expressed in various cardiovascular conditions [Arrell et al., 2001a; Heinke et al., 1998; 
Heinke et al., 1999; Pleissner et al., 1998; Schwertz et al., 2002; Sironi et al., 2001; Weekes 
et al., 1999; Weekes et al., 2003]. A number of significantly altered proteins have been 
identified in the ventricular tissue of bovine with delated cardiomyopathy [Weekes et al., 
1999], myocardial issue of rabbits with myocardial ischemia and reperfusion injury 
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[Schwertz et al., 2002] and in cardiac tissue of mice with cardiovascular complications of 
AIDS with chronic alcohol consumption [Weekes et al., 2003]. By compared with human 
expression pattern, these proteins can be further examined and determined as potential 
biomarkers for characterizing the heart diseases.  
 Similar approaches were applied to study human heart and revealed several 
characteristic protein markers for dilated cardiomyopathy [Corbett et al., 1998; Pleissner et 
al., 1997]. Researches into the discovery of autoantibodies in the sera of patients with 
myocarditis [Pankuweit et al., 1997], idiopathic dilated cardiomyopathy [Pohlner et al., 1997] 
and rheumatic heart disease [Tontsch et al., 2000] were also performed and resulted in the 
identification of some particular antigens including creatine kinase, dihydrolipoamide 
dehydrogenase, nicotinamide-adenine dinucleotide dehydrogenase and ubiquinol-
cytochrome-C reductase. Other studies looked at the modification and diversification of heat 
shock protein 27 [Scheler et al., 1997a; Scheler et al., 1999] and apolipoproteins A-I & II 
[Asztalos et al., 2000; Dayal and Ertel 2002], the well-known markers for cardiac diseases, in 
response to different myocardial conditions. Identification and quantification of the 
distributing profiles of these proteins may form characteristic patterns for classifying heart 
diseases.  
Arthritis, hepatitis and others 
 Proteomic technologies have also been used to study inflammatory and immune 
diseases. Rheumatoid arthritis (RA) is one of the autoimmune diseases that have been 
subjected to proteomic analysis for novel autoantigens or autoantibodies in sera as 
biomarkers of the disease [Hueber et al., 2002]. A sera autoantibody to a 68 kDa antigen 
detected in RA synovial membranes can be a positive marker as it demonstrated a high 
sensitivity of 64% and specificity of 99% in distinguishing RA from non-RA and other 
rheumatic diseases [Blass et al., 1995], while anti-ribonucleoproteins C1/C2 present in 
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systemic sclerosis and psoriatic arthritis may serve as a negative marker for their absence in 
RA sera [Heegaard et al., 2000]. Another potential diagnostic autoantibody, anti-alpha-
enolase, was identified through analyzing serum samples of 255 patients with very early 
arthritis, and the antibody has a specificity of 97% for RA [Saulot et al., 2002].  In addition, 
2-DE technique has also been employed to detect the protein alterations in RA salivary 
[Beeley and Khoo 1999] and synovial fluid [Smith et al., 2001] and the potential of 
quantitative analysis of protein expression in forming the basis for new diagnostic methods 
has been discussed in these studies.   
 Since chronic infection with hepatitis B or C virus (HBV, HCV) is a major risk factor 
for the development of HCC, most proteomic studies concerning hepatitis focused on the 
HBV- and HCV-related HCC [Le Naour et al., 2002; Seow et al., 2001; Steel et al., 2001]. 
We have initiated a project using proteomic technology to globally examine HBV infected 
serum samples aiming at searching for serological biomarkers for the diagnosis of HBV liver 
inflammation, which still relies on biopsy test [He et al., 2003b]. Compared with normal and 
HBV-negative samples, at least seven proteins in HBV-positive sera were found significantly 
changed in both expression quantity and patterns. Some of these alterations reflect the 
difference between low and higher stages of inflammation. We are evaluating if a 
combination index integrating the alterations of these proteins can be a useful biomarker for 
HBV diagnosis and therapy.   
 Biomarker discovery by proteomics for other diseases is relatively limited but 
promising. For example, a complementary antigen, Mtb81, has been identified and claimed to 
be a novel serological marker for the diagnosis of tuberculosis co-infected with human 
immunodeficiency virus [Hendrickson et al., 2000]. Cystatin C, detected in cerebrospinal 
fluid by SELDI technology, has been believed to be a biomarker for pain in humans [Mannes 
et al., 2003].  
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 APPLICATION OF PROTEOMICS IN DRUG DEVELOPMENT 
 Drug-development process involves many steps, including target identification, lead 
selection, small-molecular screening and optimization, and clinical testing. Proteomics is a 
promising approach in identification of protein targets and biochemical pathways involved in 
disease process and thus plays an important role in drug development. By studying 
interrelationships between proteins that occur in health and disease, proteomics contributes 
insight into determination of the pathophysiological basis for target identification. By 
charactering the protein expression profiles following drug treatment, proteomics provides 
molecular information to study the mechanistic basis for drug action and toxicity. Specific 
biomarkers identified by proteomics may serve as protein signatures to screen drug for its 
efficacy, resistance and optimization. In this regard, some subdisciplines such as chemical 
proteomics [Jeffery and Bogyo 2003], topological proteomics [Owens 2001], clinical 
proteomics [Krieg et al., 2002], toxicoproteomics [Steiner and Anderson 2000] and 
pharmacoproteomics [Kennedy 2002; Meister 2002] have been created to recognize the 
special contribution of proteomics in drug discovery. It is anticipated that the increasing 
promise of proteomics, together with the vast genetic information provided by genomics, will 
rationally revolutionize the target validation and drug development process.   
Identification of drug targets 
 Proteins constitute the majority of drug targets on which drug design processes are 
initiated. Proteomics is an effective means to detect the targets by globally examining the 
protein expression alternation and protein-protein interactions occur in disease process and/or 
after drug treatment. Several recent reviews summarized the application of proteomics in 
identification of novel drug targets for leukemias [Hanash et al., 2002], Mycobacterium 
tuberculosis [Betts 2002], and chronic skeletal diseases [Cho and Nuttall 2002]. Proteomic 
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analyses on pathogen-host interactions in chlamydial disease [Coombes et al., 2002] and in 
HCV and HIV [Tang et al., 2002] were also carried out to reveal the cellular proteins that 
physically interact with viral proteins and thus represent potential drug targets.  
 A common strategy in target identification is to analyze the proteomic profiles of cells 
treated by a growth factor or a regulatory enzyme. By compared with untreated cells, the 
altered proteins in the gene network regulation or signaling pathway in response to the 
treatment will be identified. Examples using this method include the identification of 
cytokine regulated targets in human intestinal epithelial cells [Barcelo-Batllori et al., 2002], 
potential targets of transforming growth factor-beta in lung epithelial cells [Kanamoto et al., 
2002], and cellular targets regulated by the 12-phorbol 13-myristate acetate-stimulated 
MKK/ERK cascade in human erytholeukemia K562 cells [Lewis et al., 2000]. A similar 
approach to discover the targets in signaling pathways is to focus on the phosphorylated sub-
proteomes isolated by immunoprecipitation prior to 2-DE separation. With this approach, 
novel signaling proteins or potential drug targets have been detected in primary human 
lymphocyte treated with IFN-alpha or IL2 [Stancato and Petricoin, III 2001] and in human 
platelets after thrombin activation [Maguire et al., 2002].  
 Analyzing the proteomic profiles after treatment by a known drug is a similar strategy 
for the identification of new target proteins and for getting new insight into the mechanism of 
action for better drug design. With this method, HSP27 has been found to be a potential 
modulated target for antitumor drugs in breast cancer [Chen et al., 2002b], mortalin an 
antiapoptotic protein in vascular smooth muscle cells [Taurin et al., 2002], aldehyde 
dehydrogenase 1 and quinone reductase 2 selective targets of the quinolines in red blood cell 
purine binding proteome [Graves et al., 2002] and several cellular stress proteins to be new 
targets of lovastatin, a lipid lowering agent, in liver [Steiner et al., 2000]. 
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 Chemical proteomics is another primary approach for target identification. Chemical 
proteomics distills a specific group of proteins from a complex proteome by attaching 
chemical probes to the specific proteins which can then be studied in detail [Adam et al., 
2002b; Jeffery and Bogyo 2003]. Chemical probes targeting cysteine protease have been used 
to identify protein targets in processes such as cellular apoptosis [Faleiro et al., 1997], 
cataract formation [Baruch et al., 2001] and infection with malaria parasite [Greenbaum et 
al., 2002]. Other activity-based chemical probes have also been used in protein profiling 
under a disease state or condition to detect proteins distinguishable based on their activity and 
affinity with the chemical tags [Adam et al., 2002c; Jessani et al., 2002; Lind et al., 2002]. 
Besides, new chemical probes that target serine hydrolase [Kidd et al., 2001] and phenyl 
sulfate [Adam et al., 2002d] and non-directed activity-based probes [Adam et al., 2001] have 
been synthesized. Recently, two new techniques of chemical proteomics called fluorophore-
assisted light inactivation (FALI) and chromophore-assisted laser inactivation (CALI) were 
introduced for protein target identification and validation [Beck et al., 2002; Rubenwolf et al., 
2002]. 
 In a more systematic way, Patterson described a large-scale proteomics-based target 
discovery platform consisting of cell biology, chemical proteomics and bioinformatics 
technology [Patterson 2002]. By using isotope labeling for quantitatively analysis of protein 
expression and correlating with gene-specific mRNA, the differences in the expression levels 
of nucleic acid and proteins suggest drug targets that directly cause disease or reveal 
biochemical pathways that could be modulated by bioactive molecules. This system has been 
evaluated by applying it to study continuous cell lines derived from human pancreatic 
adenocarcinomas [Patterson 2002].  
 Other studies are based on the recognition between proteins and antibodies or specific 
peptides to identify the binding partners or sites with potential role in therapeutics. The 
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examples include the determination of conformational immunogenic sites by proteomic 
mapping of patient sera with post-therapy HACA [Spencer et al., 2002] and the identification 
of interaction partners of a tumor suppressor peptide, p21cip1/waf1 [Gururaja et al., 2003].  
Action mechanism of drugs 
 Numerous proteomic studies have been performed to investigate the drug mechanism 
of action, biochemical basis of drug activity and cellular pathways that drugs act on. The 
resulting data provided novel insights into drug action modes and elucidated the new 
modulating factors for new drug design. Differential protein expression profiling is a 
commonly used approach which examines the comprehensive protein alteration after drug 
treatment to elicit new drug-associated parameters missed by conventional method. By 
characterizing the altered proteins using this approach in human tumors, the drug effects and 
regulated pathways have been investigated in Burkitt lymphoma cells treated with drug 5’-
azacytidine [Poirier et al., 2001], in A549 lung adenocarcinoma cells stimulated with a 
synthetic cyclin-dependent kinase inhibitor [Kovarova et al., 2002], in colon cancer cells 
treated with butyrate [Tan et al., 2002], in acute promyelocytic leukemia cells induced by 
retinoic acid [Wan et al., 2001], and in renal cell carcinoma cells treated with interferon-
gamma [Lichtenfels et al., 2002]. Other researchers addressed the drug action using animal 
cells, including probing for isoproterenol-stimulated signal transduction pathways in the rat 
C6 glioma cell [Storm and Khawaja 1999] and studying the antitumor activities of 
Ganoderma lucidum extracts in mouse spleen cells [Wang et al., 2002]. Animal models have 
also been directly utilized to study the drug mechanisms such as the inflammatory effects 
stimulated by interleukin and interferon in rat trigeminal ganglia [Friso et al., 2001], insulin 
processing mediated by insulin sensitizer drug rosiglitazone in pancreatic islets of obese mice 
[Sanchez et al., 2002] and the actions of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats [Bruno et 
al., 2002]. 
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 Peroxisome proliferators (PPs) are a group of chemicals that induce hepatic 
peroxisome proliferation, suppression of apoptosis, liver tumor formation and beta-oxidation 
of fatty acids. The biochemical response of PPs is mediated by PPs-activated receptor but the 
mechanisms underlying the mediation process and the molecular events are poorly 
understood. A number of investigations have been concentrated on the proteomic analysis of 
mouse or rat liver in response to the PPs treatment in order to delineate PPs mediated 
signaling pathways and their impacts on hepatocarcinogenesis [Chevalier et al., 2000; Chu et 
al., 2002; Edvardsson et al., 1999; Macdonald et al., 2001; White et al., 2003], and to explore 
the possible therapeutic value of PPs in diabetes [Edvardsson et al., 1999]. 
 Apart from these animal studies, some bacteria have also be examined by proteomics 
for their response to antibiotic agents or chemical stress [Bandow et al., 2003; Bruneau et al., 
2003; Duche et al., 2002; Singh et al., 2001]. 2-DE was used to profile the bacterial proteins 
after treatment with antibiotics and alternatives. By comparing and characterizing the protein 
expressions, researchers aimed at obtaining new information on the antibiotic mechanisms 
and classifying novel drug candidates with unknown mechanisms of action.   
Drug toxicity and screening 
 Another topic of proteomics application in drug development is the measurement of 
drug toxicity, including studies on mechanistic toxicology for evaluating current drugs and on 
predictive toxicology for screening new drug candidates [Hellmold et al., 2002; Kennedy 
2002]. Drug side-effects are common problems but the action mechanisms of the drug 
toxicity on human organs are largely unknown. In a typical proteomic experiment, protein 
extracts from a targeted organ after overdose or overtime dosing of a drug are separated by 
means of 2-DE or ProteinChips and the differentially expressed proteins are identified and 
analyzed. Further characterization of these altered proteins helps us understand the 
mechanism of toxicity for drug re-design and improvement, and the elicited drug-associated 
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proteins can be used as predictive markers of toxicity for classifying compounds and 
screening large numbers of drug candidates.  
Currently, most of studies have been focused on defining the mechanistic basis for 
hepato- and renal toxicity of various drugs such as acetaminophen [Fountoulakis et al., 2000; 
Ruepp et al., 2002], pyrimidine derivatives [Newsholme et al., 2000], methapyrilene, 
cyproterone acetate and dexamethasone [Man et al., 2002], and 4-aminophenol, D-serine and 
cisplatin [Bandara et al., 2003]. In many cases, specific proteins were identified and shown to 
correlate with molecular pathways of cellular toxicity of the drugs. Cardiovascular system is 
another common site that suffers drug toxicity. As demonstrated by conventional studies, 
cardiotoxicity could occur through various cellular and molecular mechanisms. Proteomics 
study on drug cardiotoxicity may present us a more comprehensive picture depicting how 
drug effects occur in heart and vascular system. Preliminary studies in this regard have been 
performed [Bandara and Kennedy 2002; Herman et al., 2001; Scheler et al., 1997b]. Attempt 
has also been made to utilize the specific proteins as molecular signatures for studying or 
evaluating other drugs [Man et al., 2002]. In addition, Randic and Basak developed a new 
mathematical method for characterization of effects of different toxic agents on the cellular 
proteome, aiming to graphically illustrate the differential protein expression between normal 
and drug-treated samples for understanding drug toxicity [Randic and Basak 2002]. In 
parallel to the drug toxicity study, the cellular mechanisms of drug resistance in some 
diseases such as pneumonia [Cash et al., 1999], lymphocytic leukemia [Voss et al., 2001] and 
myeloma [Mitsiades et al., 2003] have also been explored by employing proteomic 
technology.  
 Studies on drug toxicity may not only elucidate the mechanism of toxic damage but 
also detect toxin-associated proteins, which can be used as markers of toxicity for drug 
screening. A full drug-screening program involves the establishment of comprehensive 
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databases integrated with techniques and data from genomics, proteomics and bioinformatics. 
For the proteomics part, these data are a combination of protein expressions of cells or 
organisms specifically in response to drug treatment resulting in unique expression patterns, 
molecular fingerprints, indicatives of drug efficacy and potential toxicity. These information 
will obviously accelerate the lead identification and improve the optimization of drug 
efficacy and safety in pre-clinical and clinical studies. One attempt to set up a proteomic 
program for drug screening was taken by Gianazza and co-workers [Gianazza et al., 2002], 
who annotated 2-DE maps of rat serum proteins under control and experimental conditions 
with emphasis on species-specific components and the effects of acute and chronic 
inflammation. Anti-inflammatory drugs were screened and tested for their efficacy and 
toxicity on adjuvant arthritis, the correlation between biochemical parameters and therapeutic 
findings from the screening proved the sensitivity of the procedure in revealing “side-effects” 
of the test drugs.  
 In a recent report, Toledo-Sherman and Chen introduced a high-throughput virtual 
screening platform for drug selection by integrating genomics and proteomics initiatives 
[Toledo-Sherman and Chen 2002]. This platform emphasized the techniques adaptable to 
high-throughput that can tackle multiple targets and therapeutic areas simultaneously. At the 
core of this program, virtual screening relies on a structure-based docking and ranking 
method to identify bioactive molecules in compound library database. In contrast, another 
new method using the free binding energy between a ligand and receptor as a scoring strategy 
to screen drug candidates has been proposed [Bock and Gough 2002]. A validation 
experiment with 2,671 samples demonstrated the effectiveness and sensitivity of the new 
method. Additionally, a proteomic map and database of lymphoblastoid proteins has been 
constructed for analyzing drug effects and lymphocyte cell diseases [Caron et al., 2002].    
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CONCLUSIONS 
 Proteomics is established on the basis of the tremendous technique advances in 
genomics, protein separation and analysis. Proteomics features a global examination of 
protein expressions and thus the corresponding molecular events and cellular pathway 
interruptions in response to a certain disease condition can be inspected in a comprehensive 
and integrated way. Numerous efforts and progress have been made in proteomics technology 
in the last few years, its application in biomarker discovery and drug development is still at 
its early age, however. Improvements are still needed in rising the capacity for analyzing 
large size of samples, refining the resolution for separating low abundant proteins and 
increasing the sensitivity for identifying small amounts of proteins by MS. High-throughput 
proteomic screening platforms integrated with genomics and bioinformatics for identifying 
biomarkers, drug targets and drug leads represented one of the developing directions. 
Explorations in pre-fractionation of sub-proteomes for better resolution and in chemical 
probes for higher sensitivity and specificity are also encouraging. It can be anticipated that, 
by complement with other new technologies, proteomics holds great potential for identifying 
many specific biomarkers for clinical diagnosis, large source of drug targets for therapeutic 
intervention, and monitoring markers of drug toxicity and efficacy for drug screening and 
design.  
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